8-K: Surrozen Announces Second Quarter 2024 Financial Results and Clinical Trial Progress

Surrozen reported its second quarter 2024 financial results, highlighted by progress in clinical trials for SZN-043 and advancements in their SWEETS technology platform.

Summary

• Surrozen announced its financial results for the second quarter of 2024, ending June 30th.
• The company's cash and cash equivalents increased to $37.8 million, up from $27.3 million at the end of the previous quarter.
• Research and development expenses decreased to $5.3 million, compared to $6.9 million in the same period last year, due to restructuring and discontinuation of a clinical program.
• General and administrative expenses increased to $3.7 million, up from $3.3 million in the same period last year, primarily due to employee retention tax credits received in 2023.
• The company reported a net loss of $25.3 million for the quarter, compared to a net loss of $9.4 million in the same period last year, primarily due to a loss on issuance of common stock, pre-funded warrants and warrants.
• Surrozen is actively enrolling patients in the Phase 1b trial for SZN-043, with proof-of-concept data expected in the first half of 2025.
• The company presented Phase 1a trial results for SZN-043 at the European Association for the Study of the Liver (EASL) in June 2024, showing the treatment was safe and well-tolerated.
• Surrozen also published a study on their SWEETS technology platform, demonstrating robust Wnt signal activation through targeted protein degradation.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive clinical trial progress and a strong cash position, but a significant net loss and increased expenses temper the overall sentiment.

Positives

• The company's cash position improved significantly, increasing to $37.8 million.
• The Phase 1b trial for SZN-043 is underway, with proof-of-concept data expected in the first half of 2025.
• The Phase 1a trial results for SZN-043 showed promising safety and tolerability.
• The publication of the SWEETS technology study highlights the potential of their platform.
• The partnership with Boehringer Ingelheim has the potential to generate a $10.0 million milestone payment in 2024.

Negatives

• The company experienced a significant net loss of $25.3 million for the quarter.
• The loss on issuance of common stock, pre-funded warrants and warrants was $20.4 million.
• Research and development expenses decreased, but this was due to restructuring and discontinuation of a clinical program.
• General and administrative expenses increased compared to the same period last year.

Risks

• The company's ability to fund its clinical trials and development efforts is dependent on existing funds or additional fundraising.
• The success of clinical trials for SZN-043 and SZN-413 is not guaranteed.
• The company faces risks related to global economic, political, regulatory, and market conditions.
• There is a risk that actual results could differ materially from the forward-looking statements.

Future Outlook

Surrozen anticipates proof-of-concept data from the SZN-043 Phase 1b clinical trial in the first half of 2025 and the potential to nominate the lead Fzd-4 targeted Wnt agonist development candidate in 2024, which would trigger a $10.0 million milestone payment.

Management Comments

• We made significant progress in the second quarter with accomplishment of key milestones including dosing the first patient in the SZN-043 Phase 1b trial, presenting first-in-human data from the SZN-043 Phase 1a trial at EASL and publishing new information regarding the promise of our proprietary SWEETS platform, said Craig Parker, President and Chief Executive Officer of Surrozen.
• Surrozen is focused on transforming the treatment of severe diseases of the liver and eye, and we look forward to proof-of-concept data from the SZN-043 Phase 1b clinical trial in the first half of 2025.

Industry Context

Surrozen is operating in the competitive biotechnology sector, focusing on Wnt pathway modulation for tissue repair and regeneration, a field with significant potential for treating degenerative diseases. The partnership with Boehringer Ingelheim highlights the industry's interest in novel therapeutic approaches for retinal diseases.

Comparison to Industry Standards

• Surrozen's focus on Wnt pathway modulation is similar to other biotech companies exploring regenerative medicine, such as those working on stem cell therapies or gene editing.
• The company's progress with SZN-043 in liver disease is comparable to other companies developing treatments for conditions like alcoholic hepatitis, such as Intercept Pharmaceuticals with their OCA drug.
• The partnership with Boehringer Ingelheim for retinal diseases is similar to other collaborations in the ophthalmology space, such as the partnership between Regeneron and Bayer for Eylea.
• The reported net loss of $25.3 million is not unusual for a clinical-stage biotech company, as these companies often incur significant R&D expenses before generating revenue.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the clinical trial progress.
• Employees may be affected by the restructuring and changes in expenses.
• Customers and patients may benefit from the development of new treatments for liver and retinal diseases.
• Partners like Boehringer Ingelheim will be interested in the progress of SZN-413.

Next Steps

• Continue enrollment in the Phase 1b trial for SZN-043.
• Anticipate proof-of-concept data from the SZN-043 Phase 1b clinical trial in the first half of 2025.
• Potentially nominate the lead Fzd-4 targeted Wnt agonist development candidate in 2024.
• File the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 with the SEC.

Key Dates

Keywords

Surrozen, SZN-043, SZN-413, Wnt pathway, SWEETS technology, clinical trial, liver disease, retinal disease, biotechnology, Boehringer Ingelheim